SECURITIES AND EXCHANGE COMMISSION
                                  
                         WASHINGTON, D.C.  20549

                         _______________________                   
               
                              FORM 10-KSB
                        ________________________
                                  
              ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                  THE SECURITIES EXCHANGE ACT OF 1934
                                  
   For the fiscal year ended                     Commission file
       December 31, 1996                         number 0-27610
 
                                  
                             LCA-VISION INC.
                                  
   A Delaware Corporation                          I.R.S. Employer
                                     Identification No. 11-2882328
                                  
                 7840 Montgomery Road, Cincinnati, Ohio 45236
                     Telephone Number (513) 792-9292
                       _________________________
                                  
  Securities registered pursuant to Section 12(b) of the Act: None
                                  
  Securities registered pursuant to Section 12(g) of the Act:
                                  
                             Title of class
                                  
                      Common Stock, $.001 par value

    Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by  Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the past 12 months (or for
such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for
the past 90 days.  Yes  [X]    No [  ]
                      ________________________

     Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of Regulation S-B is not contained in this
form, and no disclosure will be contained, to the best of
registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form
10-KSB or any amendment to this Form 10-KSB. [ X ]
                     ________________________

     As of March 20, 1997 the latest practicable date, 19,599,234
shares of Common Stock were outstanding.  The aggregate market
value of Common Stock held by non-affiliates was approximately
$9,005,085 at that date.

                     ________________________

                   DOCUMENTS INCORPORATED BY REFERENCE

     List hereunder the following documents if incorporated by
reference and the part of the Form 10-KSB into which the document
is incorporated: None 


Transitional Small Business Disclosure Format (Check one): 
 Yes ____         No X
                        


                               PART I

Item 1.  Description of Business.

Background, History of Company  

     LCA-Vision Inc. (the "Company" or "LCA-Vision") was 
incorporated in Delaware in 1987 under the name Kessef
Technologies Inc.  In 1988, Kessef Technologies Inc., merged with
Maxoil Incorporated, a California corporation, under the charter
of Kessef Technologies, Inc. changing the name of the Company to
Maxoil Incorporated.  Maxoil Incorporated formerly operated a
business developing, managing and syndicating oil and gas
investments and in 1988 had completed an initial public offering
issuing 1,500,000 shares of its common stock to the public.  Since
December 31, 1993, Maxoil Incorporated had been an inactive, non-operational 
corporation.

     In July, 1995, Stephen N. Joffe, M.D. purchased a majority of
the outstanding shares of the common stock and preferred stock of
Maxoil Incorporated and amended the Certificate of Incorporation
to change the name to LCA-Vision Inc. and to effect a one-for-ten
reverse stock split.  Dr. Joffe also moved the corporate
headquarters to 7840 Montgomery Road, Cincinnati, Ohio.  

     On August 31, 1995, LCA-Vision, through its wholly-owned
subsidiary, LCA Canada, Inc., acquired all of the stock of the
Toronto Laservision Centre, Inc., intending to operate it as a
wholly-owned subsidiary of the Company.  On September 29, 1995,
Laser Centers of America, Inc., a Delaware corporation ("LCA")
founded by Stephen Joffe, merged into LCA-Vision.  The shares of
LCA-Vision were quoted on Nasdaq's over-the-counter electronic
bulletin board under the symbol LCAV.  On January 25, 1996, LCA-Vision Common 
Stock began trading on the Nasdaq SmallCap Market.

Business Overview

LCA-Vision is a manager of laser and minimally invasive surgery
programs for hospitals and medical centers and is a leading
developer and operator of free-standing laser refractive eye
surgery centers in the U.S. and abroad.

In the mid-1980s, the Company pioneered the multi-specialty laser
surgery center business, and, during its successful 10 year
operating history, was involved in the implementation of over 80
hospital-based, multi-specialty surgery programs.  Based on this
experience, the Company has developed an expertise in managing and
promoting new laser surgery techniques and technologies.  The
Company continues to manage 26 hospital laser surgery programs on
a contract basis and has used the cash flow from these operations
to partially fund the expansion of its refractive eye surgery
business. 

Since 1991, the Company has applied its laser operating expertise
to the field of refractive eye surgery and particularly to
photorefractive keratectomy, a procedure in which lasers are used
to permanently correct nearsightedness and other eye conditions. 
The Company believes that it is one of the three largest operators
of free-standing refractive surgery centers in the U.S.  As of
December 31, 1996, the Company had twelve refractive surgery
facilities in the U.S., two in Ontario, Canada (Toronto and Ft.
Erie) and one in Helsinki, Finland.  In addition, the Company has
opened two new centers in January 1997 in Albany, New York and
Mountain View, California.  In total, the Company currently
operates 17 laser vision correction centers.

Laser Refractive Surgery Centers

The laser refractive surgery centers operated by the Company
provide the facilities, equipment and support services necessary
for performing various corrective eye surgeries that employ state-of-the-art  
laser technologies.  Each center is equipped with one
or more laser systems in addition to corneal topography
instruments, ophthalmic examination equipment, computer systems
and standard office equipment.  Each center is typically staffed
by a center director, an office administrator and a laser
technician. Ophthalmologists using the Company's facilities have
completed extensive FDA-mandated training sessions and have met
the qualification criteria of the Company.  

The Company's laser refractive surgery centers operate under the
tradename LCA-Vision Laser Centers of Excellence .  The surgeries
currently performed in the Company's centers primarily include PRK
for the treatment of nearsightedness.  As new laser-based surgical
procedures are approved by the FDA, the Company will accommodate
the service requirements for these procedures as well.
By using the Company's facilities, physicians are able to
concentrate on treating patients and are freed from the financial
and management requirements associated with establishing and
operating a surgery center.  Additionally, participating
physicians benefit from the Company's marketing skills and
programs (such as its toll-free 800 numbers) in terms of
identifying and capturing potential new patients.  Finally, many
of the back office administrative and financial functions are
performed more efficiently in a centralized operation that can
leverage the volume of numerous individual facilities.
Since PRK is not generally reimbursable by third party payers, the
Company offers several financing alternatives.  Customers can pay
for the procedure with cash, bank check, money order or credit
card.  In addition, the Company offers a 90-days-same-as-cash
payment plan that has no application fee and a one hour credit
decision time.  The plan, offered by an unaffiliated finance
company at a 14.9% interest rate for qualified applicants, allows
a customer to delay all payments for 90 days and then to pay a
fixed monthly amount based on the amount of the initial down
payment.  The Company also offers information regarding
installment plans, insurance coverage, home equity loans and
payment through employer flexible benefit plan.  The Company bears
no credit risk of any of these options.

The Company has had extensive experience with PRK, having operated
its laser refractive surgery center in Toronto since 1991. 
Physicians have performed over 5,000 refractive surgeries,
primarily PRK, at this site alone and, since the approval of PRK
by the FDA, physicians have performed over 2,000 refractive
surgeries in the Company's U.S. centers.  The results of a Company
study of the initial 1,150 procedures performed at its U.S.
centers indicated that, of those procedures with at least six
months of follow-up, 85% of the eyes were corrected to between
20/20 and 20/25 and 97% were corrected to at least 20/40. 
Importantly, the Company is also able to gain experience with new
laser technologies and surgery techniques in its Toronto, Ft. Erie
and Helsinki centers in advance of their FDA approval in the U.S.  

Toronto Laservision Centre, Inc.

     The Toronto Laservision Centre, Inc. has been performing PRK
surgery in Toronto, Canada since 1991.  Toronto differs from the
Company's U.S. centers in that its fixed costs are approximately
twice the level of a typical U.S. operation and its price per
procedure is slightly lower in U.S. dollar terms.  It should be
noted that, following the FDA approval of PRK for use in the U.S.,
the number of U.S. patients referred to Toronto declined during
1996.

Expansion of U.S. Refractive Surgery Centers

     The Company's only operating eye care center as of the third
quarter of 1995 was Toronto (which opened in 1991).  Since that
time, the Company has successfully opened 16 additional eye care
centers. 

     The Company seeks to differentiate its centers in the
marketplace by providing locations and treatment environments that
meet patient and doctor preferences.  Additionally, if the Company
enters a market with an existing laser system (either Summit or
VISX), it will typically install the other system if  that system
better satisfies the needs of local opthalmologists. 

The following table sets forth the total number of PRK and LASIK
procedures performed at each of the Company's facilities since
January 1, 1996.

FACILITY           1996 TOTAL     Date Opened
_____________      __________     ___________
Baltimore             481             2/96
Cincinnati            423            12/95
Cleveland             266             1/96
Savannah              250             2/96
Toledo                192             4/96
New York City         151            12/95
Dayton                134             4/96
Charlotte              74             9/96
Buffalo                15            12/96
Westchester            12             7/96
Clearwater             10            11/96
Columbus                7            11/96
                   ________
   U.S. 
Facilities          2,015             

Toronto             1,489             8/91
Ft. Erie               53            11/96
Helsinki               63            10/96
                   ________
   All 
Facilities          3,620

(1)  Toronto results exclude 179, 157 and 41 referrals of U.S.
patients from another company for the first three quarters of
1996, respectively, that halted such referrals on July 31, 1996.

(2) Acquired.

The Company has now begun implementing its excimer ophthalmic
surgery centers in the U.S. using Summit and VISX lasers to
perform PRK on nearsighted patients.  Both Summit and VISX lasers
are subject to a royalty fee of $250 per procedure performed (the
"Pillar Point Royalty").  The following table sets forth the
locations at which the Company uses various laser systems.

Summit          VISX            Nidek       Chiron
__________      ________        ________    _______
Cincinnati      Columbus        Helsinki    Toronto
New York City   Mountain View   
Cleveland       Charlotte          
Savannah        Albany          
Dayton          St. Petersburg  Sunrise     LaserSight
                                _______     __________
Toledo          Baltimore       Toronto     Baltimore
Westchester     Toronto          
Buffalo     
Ft. Erie (Apex Plus)               
Toronto (Apex Plus)     

Currently, a total of 908 doctors have privileges and have been
credentialed at LCA-Vision centers.  Of this total, 396 are
ophthalmologists and 512 are optometrists.  Many of these
physicians have signed non-compete agreements with the Company
that limit their ability to perform PRK procedures at other
facilities for a period of two years.

Competition

As a leading provider of PRK, the Company competes with several
surgical and non-surgical treatments to correct refractive
disorders, including eyeglasses, contact lenses, other types of
refractive surgery (such as radial keratotomy), corneal implants
and other technologies currently under development.   Eye care
services in the U.S., including PRK, are delivered through a
fragmented system of local providers, including individual or
small groups of opticians, optometrists and ophthalmologists and
chains of retail optical stores and multi-site eye care centers. 
Refractive surgery center chains, such as the Company, are a
specialized type of multi-site eye care center that primarily
provide PRK.

Of the 16,500 ophthalmologists in the U.S., approximately 4,800
have completed the first phase of the FDA-mandated training
program required for excimer laser surgery and over 1,260 have
completed the second phase which certifies them to treat patients. 
The Company believes that approximately 70% of all PRK procedures
are currently performed by an individual doctor or a small
unaffiliated practice group.

In addition to providing eyeglasses and contact lenses, retail
optical chains could potentially provide PRK.  Certain chains have
entered the PRK market with limited success and have cut back
their involvement in the industry.  Other retail optical chains
are not currently focusing on providing refractive surgery.

Among the refractive surgery center chains, the Company is the
third largest provider in terms of number of facilities after only
Summit (with approximately 20 centers) and Laser Vision Centers,
Inc. ("LVCI") (with approximately 20 centers).  Summit is also one
of the two FDA-approved manufacturers of refractive lasers, and it
purchased Lens Express, a contact lens manufacturer and
distributor, in 1996.  On January 31, 1997, however, Summit
announced its intention to either sell or spin-off its chain of
vision correction centers in order to better focus on its core
business of manufacturing laser equipment.  Summit is listed on
the Nasdaq National Market under the symbol "BEAM."  LVCI is a PRK
provider with centers in North America and Europe and is listed on
the Nasdaq National Market under the symbol "LVCI."  Other
competing refractive surgery center chains include TLC The Laser
Center (which recently acquired the laser center operations of
20/20), Sight Resources Corp., Beacon Eye, Vista Technologies and
Global Vision.

Multi-Specialty Surgery Programs

In the mid-1980s, the Company pioneered the multi-specialty laser
surgery center business and, during its successful 10 year
operating history, has implemented over 80 such surgery programs
in the U.S., Canada and Asia. The Company has developed, over that
time frame, a national infrastructure which includes centralized
marketing, management and financial functions.  The Company
believes that it is the only independent organization providing
these management services to the health care provider market. 
Based on this unique experience, the Company has developed an
expertise in managing, marketing and promoting new laser surgery
techniques and technologies.

The Company continues to manage 26 multi-specialty surgery
programs at various medical facilities on a contract basis.  These
facilities are located in eighteen states, primarily in the
Midwest and Southeast.  The contracts with these facilities
generally range in duration from one to three years with options
to renew.  The contract services are provided to the participating
hospitals on an exclusive basis within a defined market. 

The type of laser or minimally-invasive surgery offered at any of
the hospitals which contract for the Company's services is
dependent upon the expertise of the professionals who utilize the
center and the needs of the specific hospital.  Many surgical and
medical specialties currently and potentially will be able to
utilize lasers in their procedures.  Among them are ophthalmology,
gynecology, otorhinolaryngology, gastroenterology, pulmonology,
urology, neurosurgery, general surgery, plastic surgery,
dermatology, vascular surgery, thoracic and cardiac surgery,
oncology, oral/maxillofacial, orthopedics, pediatric surgery,
podiatry, radiology, burns, traumatology, rheumatology, colo-rectal surgery and 
sports medicine.

The Company structures its contractual arrangement with facilities
to match compensation with the value of the specific services it
provides.  While the exact terms of the contracts often vary, the
basic structure is generally the same.  The Company is paid a
fixed amount for the initial work performed to render a center
operational and then receives compensation to service a center on
an ongoing basis.  For example, the Company receives fees for its
ongoing education program and advertising program. The Company
also is compensated for the success of the center, which creates
incentives to increase surgical volume or reduce surgical costs. 
Under a contract tied to laser procedures, the Company is usually
paid a fixed amount for each laser surgical procedure performed in
the surgery center.  Amounts specified per procedure vary from
contract to contract.

The renewal of the Company's contracts with the hospital providers
is becoming increasingly difficult due to increasing price
pressures and the lengthening of the sales cycle.  Hospital
providers and other entities are being driven to cut costs and
scale back their operations, sometimes including the programs that
the Company manages.  The Company's existing contracts, however,
provide significant positive cash flow which the Company is using
to partially fund the expansion of its refractive surgery
business.  In addition, most of the corporate resources previously
engaged in the contract management business have been reassigned
to the refractive surgery business, which the Company believes has
much greater long-term potential.

Program Development Services

The Company has developed a unique set of skills relating to the
successful development and management of surgery programs for
health care providers such as hospitals and medical centers. 
These skills are directly transferable to developing and operating
a refractive laser surgery center.  These skills include (1)
designing the facility, (2) creating an education program, (3)
developing a marketing plan and patient referral system, (4)
providing ongoing employee training and (5) recruiting and
retaining an on-site center director.

Designing the Facility   The Company assesses existing
configurations, available equipment and a facility's potential
case mix.  The Company then provides specifications for any
required changes in layout and any additional equipment that will
be needed.  Equipment required typically includes lasers, other
hardware and operating room accessories.

Creating an Education Program   Concurrent with the design and
configuration of new centers, the Company creates and implements a
comprehensive education program for the center's physicians,
nurses and technicians.  The training and education is conducted
by the Company's full-time employees as well as independent
faculty who are experts in the fields of laser surgery and other
newer surgical procedures.  The instruction provided is a
combination of lectures and "hands-on" training and is designed
for both the physicians utilizing advanced surgical techniques and
the surgical technicians and nurses supporting them.  The Company
is approved by both the Accreditation Council for Continuing
Medical Education and the Ohio Nurses Association to issue
continuing education credits to physicians and nurses,
respectively.  The Company has provided 900 educational courses to
nearly 8,300 physicians and awarded almost 65,000 continuing
education credit hours.  In addition, 145 courses were given to
3,300 registered nurses and support staff.

Developing a Marketing Plan and Patient Referral System   The
Company's marketing and advertising program is designed to build
public awareness of the benefits of laser and advanced surgery
techniques as well as to build brand recognition of the Laser and
Advanced Surgery Centers of Excellence  or LCA-Vision Laser
Centers of Excellence  tradenames.  The marketing and advertising
is provided by the Company's in-house staff and is tailored to the
demographics of the local market.  Specialized materials include
television, radio and print media advertisements and literature
designed for each stage of a center's development.  The
advertising campaign publicizes a toll-free telephone number which
services as the access point for potential patients.  This system
has succeeded in increasing both laser procedures and overall
surgical volume.

Providing Ongoing Employee Training   The Company continuously
monitors developments in lasers and advances in surgical
technology, and participating facilities continuously receive
updates on new procedures and technology.  In addition, the
Company monitors medical regulatory developments that may impact
the operation of the centers and assists the client in ensuring
compliance with applicable governmental requirements.  The Company
also assists in clinical studies and provides advanced ongoing
education for physicians and nurses.

Recruiting and Retaining an On-Site Center Director   The Company
appoints a full-time center director whose primary duties include
assisting in physician recruitment, design and implementation of
education programs, advising the center on policies and
procedures, developing safety procedures, assisting in the
credentialing process for advanced surgical operations, attending
to staffing requirements and assisting hospital medical committees
that deal with the utilization of surgical equipment.  The center
director is critical to the success of the overall program and is
usually an employee of the Company, though the health care
provider generally reimburses the Company for a portion of the
center director's salary.

Current Multi-Specialty Surgery Programs Under Contract 

Facility                                    Location    
Advanced Surgery Center of Georgia          Canton, GA
Advanced Surgery Facility-Trumbull Mem. 
  Hosp.                                     Cortland, OH
Baptist Medical Center                      Montgomery, AL
Binghamton General Hospital                 Binghamton, NY
Cabrini Medical Center                      New York, NY
Candler Hospital                            Savannah, GA
Carraway Methodist Medical Center           Birmingham, AL
Columbus-Cabrini Medical Center             Chicago, IL
Good Samaritan Hospital and Health Center   Cincinnati, OH
LCA-Center for Surgery                      Cincinnati, OH
The Medical Center of Central Georgia       Macon, GA
Methodist Medical Center of Oak Ridge       Oak Ridge, TN
Pendleton Memorial Methodist Hospital       New Orleans, LA
St. Frances Cabrini Hospital                Alexandria, LA
St. Francis Hospital of New Castle          New Castle, PA
St. Francis Medical Center                  Pittsburgh, PA
St. Francis Surgery Center   Cranberry      Pittsburgh, PA
Saint Joseph Medical Center                 Joliet, IL
St. Mary's Medical Center                   Evansville, IN
St. Patrick's Hospital of Lake Charles      Lake Charles,LA
St. Vincent's Hospital and Health Care 
   Center                                   Indianapolis, IN
Sarasota Memorial Hospital                  Sarasota, FL
The Toledo Hospital                         Toledo, OH
Trumbull Memorial Hospital                  Warren, OH
Wausau Hospital Center                      Wausau, WI
Wilson Memorial Regional Hospital           Johnson City, NY

Properties

Each of the Company's laser refractive surgery centers is located
in leased space. The laser refractive surgery centers are
generally located in professional office buildings.  Substantially
all of the laser refractive surgery centers include laser surgery
rooms, private examination rooms, and large patient waiting areas. 
The leased space ranges in size from approximately 2,000 to 6,700
square feet; with expiration dates ranging from October 1997 to
January 2003.  As of March 20, 1997, the Company had 13 wholly-owned laser 
refractive surgery centers.  The following table
details the locations of the wholly-owned laser refractive surgery
centers by state or province:

California
     Mt. View

Florida
     Clearwater

New York
     Albany
     Buffalo

North Carolina  
     Charlotte

Ohio
     Cincinnati
     Cleveland
     Columbus
     Dayton
     Toledo
     Warren

Ontario, Canada
     Ft. Erie
     Toronto

     Employees.  As of December 31, 1996, the Company had 118
employees, of whom 86 employees were full-time.  The personnel who
constitute the Company's independent faculty are doctors and other
healthcare professionals retained, when and as needed, as
independent contractors to assist with the education and training
provided by the Company to its clients.  The Company retains its
faculty from a pool of doctors or other healthcare professionals
who have agreed to provide services to the Company on an
independent contractor basis.

     Trademarks.  The Company's trademarked names have not yet
been formally registered.  Where the trademark symbol is used
herein, it is the Company's intention to claim a trademark on such
names under common law by using the "TM" symbol.  The duration of
such trademarks under common law is the length of time the Company
continues to use them.  At some point in the future, the Company
plans to formally register their trademarks with the U.S.
Trademark Office.

Item 3.  Legal Proceedings.

     Toronto Laser/Sight Centre was named as co-defendant in a
lawsuit, Sophie Nowogorski v. Dr. Herb Tanzer and Toronto
LaserSight Centre (Toronto Laservision Centre, Inc.), filed on
April 28, 1994 in the Ontario Court (General Division) by a former
patient of the Toronto LaserSight Centre claiming negligence,
breach of contract and/or assault and battery in connection with
excimer eye surgery performed n the plaintiff.  The plaintiff
claimed general damages in the amount of $500,000 (Canadian).  The
Company successfully defended against all of such claims and the
court dismissed the case without costs in December 1996.  The suit
of VISX Incorporated v. Summit Technology Incorporated involves
allegations of patent infringement in Canada.  VISX has alleged
that Summit manufactured and sold a laser system that infringed on
its patents.  In addition, VISX added as defendants eight Canadian
users of these machines, one of which, Dr. Patricia Teal, was a
shareholder of The Eye Laser Center, which was acquired by LCA-Vision in 
October 1996.  Summit is aggressively defending its
innocence and the Canadian equivalent of the U.S. American Medical
Association is defending the physicians.  LCA-Vision has not
signed a license agreement with VISX on behalf of the Summit laser
located in Ft. Erie and used by Dr. Teal.  LCA-Vision has held in
escrow U.S. $64,000 (in the form of a letter of credit) of the
acquisition payment to the shareholders of The Eye Laser Center
for settlement of any judgment based upon the time of ownership
prior to LCA-Vision's acquisition.

Item 4.  Submission of Matters to a Vote of Security Holders

     Not applicable.

                            PART II

Item 5.  Market for Registrant's Common Equity and Related
Stockholder Matters.

     The Company's Common Stock is traded in the over-the-counter
market under the symbol "LCAV."  On January 25, 1996, the Common
Stock commenced trading on the Nasdaq SmallCap Market.  On March
20, 1997, there were approximately 482 holders of record of the
Company's Common Stock.

     The following table sets forth, for the periods indicated, as
reported on Nasdaq, the range of high and low closing bids.  These
quotations reflect inter-dealer prices, without retail mark-up,
mark-down or commission, and may not necessarily represent actual
transactions.  For the periods prior to June 30, 1995, there was
no active market for the Company's Common Stock and no trading
took place.

In June 1996 the Company effected a 1 for 4 reverse stock split. 
The bid prices prior to the date of the split have been adjusted for
the split.

                                     High          Low
1995:  Third Quarter               $ 2.00       $ 1.00
       Fourth Quarter               21.00         2.52

1996:  First Quarter               $22.00       $ 6.00
       Second Quarter               11.50         3.625 
       Third Quarter                 6.25         3.625
       Fourth Quarter                4.375        2.25 

     Prior to September 29, 1995, the Company was a subchapter S
Corporation for tax purposes and periodically distributed S
Corporation dividends to its stockholders.  Subsequently, the
Company has not paid any cash dividends and does not anticipate
doing so in the future.

Item 6.  Management's Discussion and Analysis or Plan of
Operation.


Overview

     On September 29, 1995, LCA-Vision Inc. ("LCA-Vision" or the
"Company") merged with Laser Centers of America, Inc. ("LCA").  At
the time of the merger, two shareholders together owned
92% of the outstanding voting stock of LCA-Vision and 100% of
LCA's.  The financial statements reflect the historical assets and
liabilities and results of operation of LCA prior to the
merger. 

     On August 31, 1995, the Company acquired the minority
interest of Toronto Laservision Centre (the "Centre") which
provides corrective eye surgery using laser technology.  LCA
previously owned 67% of the Centre; however, it did not have
control of the activities or the business affairs of the Centre
and, accordingly, recorded its investment using the equity method
until August 31, 1995.  The operations of the Centre since August
31, 1995, are included in the consolidated financial statements of
the Company.

LCA-Vision is a leading developer and operator of free-standing
laser refractive surgery centers and manages laser and minimally
invasive surgery programs for hospitals and medical centers. 

The laser refractive surgery centers operated by the Company
provide the facilities, equipment and support services for
performing various corrective eye surgeries that employ
state-of-the-art laser technologies.  The surgeries performed in
the Company's centers primarily include photorefractive
keratectomy ("PRK") for treatment of myopia (nearsightedness). 

The Company manages 26 multi-specialty laser surgery programs at
various medical facilities on a contract basis.  The Company
structures its contractual arrangements to match compensation
with the value of the specific services it provides.  The Company
is generally paid on a fixed amount for the initial work performed
to render a center operational and then receives compensation to
service a center on an ongoing basis.  Compensation is generally
fixed based on procedures performed; based on increased surgical
volume or reduced surgical costs; or a combination of such. 
Contracts may also compensate the Company for conducting the
education and marketing programs of the surgical center and its
staff including doctors.

The Company derives its revenue from three primary sources:  (i)
fees for surgeries performed at its laser refractive surgery
centers, (ii) contractual fees for managing multi-specialty laser
surgery programs, and (iii) fees for marketing and education
programs; management fees for operating laser refractive surgery
centers of investees; and miscellaneous sources.  Miscellaneous
sources include product sales - lasers and laser surgery
instruments - which the Company is phasing out.

The Company classifies its operating expenses into the following
categories:  (a) direct operating expenses which include: (i)
laser refractive surgery centers --  labor, physician fees, Pillar
Pointroyalty fees (a royalty fee paid to the manufacturers of the
FDA-approved lasers of $250 per procedure), facility rent and
utilities, and surgical supplies; (ii) multi-specialty laser
surgery programs - - labor; and (iii) other services and products
--  labor and cost of products sold; (b) general and
administrative expenses which primarily include marketing program
costs, headquarters staff expenses and other overhead costs; (c)
center pre-opening expenses which include direct costs incurred
prior to opening a laser refractive surgery center; and (d)
depreciation and amortization.

Results of Operations

The Company's results of operations in any period are
significantly affected by the number of laser refractive surgery
centers opened and operating, the number of hospitals under
management contract, and the level of services contracted by
hospitals and others during such period.  Given the limited period
of time that the laser refractive surgery centers have been
opened, the Company's results of operations may not be indicative
of future results.  

The following table reflects the Company's expansion into laser
refractive surgery centers:

                                                                   
                                   1996       1995        1994
Operating at beginning of period
 Wholly-owned                       2

Investees                           1           1          1
 Opened/acquired during period
 Wholly-owned                       8           2

Investees                           4           1
 Operating at end of period
 Wholly-owned                      10           2
 Investees                          5           1

In January 1997 the Company opened two wholly-owned laser
refractive surgery centers.  The Company records the activity of
its investee laser refractive surgery centers using the equity
method of accounting.

Multi-specialty laser surgery programs under contract at December
31 were:  1996 -- 26, 1995 -- 38, and 1994 -- 43.

The following table shows the percentage of net revenue
represented by various expense categories reflected in the
Company's Consolidated Statement of Operations:

                                                                   
                                     Year Ended December 31,
                                                                   
                                         1996   1995       1994

     Net revenue                       100.0%   100.0%    100.0%
     Direct operating expenses          56.2     43.8      43.1
     General and administrative 
     expenses                           53.3     46.2      39.1
     Center pre-opening expenses         1.6
     Depreciation and amortization      11.6      7.6       7.4
     Operating profit (loss)           (22.7)     2.4      10.4

The following table reflects the sources of consolidated net
revenue and consolidated direct operating expenses:
                                                                   
                                       Year Ended December 31,
                                                                   
                                        1996    1995      1994
    Net Revenue
     Laser refractive surgery centers   27.0%
     Multi-specialty laser surgery 
     programs                           33.9     48.5%     49.9%

     Other                              39.1     51.5      50.1
           Total net revenue           100.0%   100.0%    100.0%

    Direct Operating Expenses
     Laser refractive surgery centers   51.1%
     Multi-specialty laser surgery 
     programs                           20.8     42.5%     41.2%

       Other                            28.2     57.5      58.8
           Total direct operating 
          expenses                     100.0%   100.0%    100.0%


Net revenue for 1996 was $13,759,838 which represents an increase
of $108,810 compared to 1995.  Revenue in 1995 decreased
$3,280,807 compared to 1994.

1996 net revenue was positively impacted by the opening of laser
refractive surgery centers.  This new source of revenue offset the
decline in marketing and education services provided to hospitals
and surgery centers.  The decline in such revenue was due in part
to the decline in the number of contracts.  In addition, the cost
reduction programs instituted by health care providers negatively
impacted their marketing and education expenditures.  Revenue from
multi-specialty laser surgery programs declined as a result of the
decreasing number of facilities under contract.

The decrease in 1995 net revenue compared to 1994 is a direct
result of the reduction in facilities under contract.

Management anticipates that the composition of future revenue will
change as more laser eye surgery centers are developed and as the
photorefractive keratectomy ("PRK"), a procedure in which lasers
are used to permanently correct nearsightedness, becomes more
widely known and accepted by ophthalmic physicians and their
patients.  Revenues from hospital-based multi-specialty centers
will be less significant to the Company while revenues from laser
eye surgery centers are expected to increase.  The extent and
degree of the shift in the Company's future revenues are subject
to significant uncertainty.

Direct operating expenses were $7,732,171 in 1996 which represents
an increase of $1,751,514 compared to 1995.  Direct operating
expenses in 1995 decreased $1,310,254 compared to 1994.

The increase in direct operating expenses is primarily a result of
the Company's expansion into the laser refractive surgery
business.  Direct operating expenses comprise the significant
fixed costs of performing the procedure as well as the costs of
maintaining a facility.  These costs will become a lesser
percentage of revenue as procedure volume increases.  Direct
operating expenses related to the other sources of revenue are
more variable and fluctuate generally with the level of revenue.
  
General and administrative expenses were $7,327,036 in 1996 which
represents an increase of $1,022,125 compared to 1995.  General
and administrative expenses in 1995 decreased $320,174 compared to
1994.  In 1996, the Company spent approximately $2,000,000 for
marketing and advertising programs to educate and inform
individuals about PRK.  Other expenses such as telephone, legal,
insurance, and repairs and maintenance increased as the Company
opened new refractive laser surgery centers.

Depreciation and amortization increased in 1996 compared to 1995
due to the increase in property and equipment, primarily equipment
for the refractive laser surgery centers.

Interest expense was $769,816 in 1996 which is an increase of
$460,352 compared to 1995.  The increase is primarily a result of
the increased borrowings related to the capitalized leases for the
lasers, borrowings under the line of credit, and the loans from
the principal shareholders.

The $545,903 gain on the sale of investment in unconsolidated
affiliate is the difference between the net selling price and the
carrying value using the equity method of accounting for the
investment in Continuum Biomedical, Inc.  This investment was sold
in the first quarter 1996 and the Company received proceeds of
$1,000,000 from the sale.

Liquidity and Capital Resources

The Company's principal capital requirements include working
capital for the financing of accounts receivable from its
multi-specialty laser surgery program contracts and the equipping
and furnishing, the continuing development of marketing programs,
and the funding of operating losses of its laser refractive
surgery centers.  To date, the Company has funded its operations
largely from internally-generated funds, lease financing, and bank
borrowings.

The Company has an $8 million line of credit, expiring July 1,
1997, which it has used to maintain its existing businesses and to
expand its laser refractive surgery center business.  Borrowings
under this line of credit were $3,438,000 at December 31, 1996. 
The Company anticipates renewing the bank line of credit prior to
its expiration.  There is, however, no assurance that the bank
will renew the line of credit or, if the line is renewed, on the
same terms and conditions.

At December 31, 1996, the Company had cash equivalents totaling
$724,026 and negative working capital of $3,186,842.  The negative
working capital is primarily due to the use of the bank line of
credit to fund the expansion of the laser refractive surgery
centers and to fund their anticipated losses.  Net cash used to
purchase property and equipment, excluding excimer lasers, and for
investment in and advances to unconsolidated affiliates, was
$4,559,711  in 1996.  Cash used by operating activities for the
year 1996 was $969,338.  Cash used in operating activities was
principally the funding of the anticipated operating losses of the
laser refractive surgery centers.

Capital of $100,000 was raised  in 1996 through the sale of common
stock in private placement transactions.  With the first year cost
of a laser refractive surgery center of approximately $1 million,
the Company has concluded that additional capital is necessary to
continue the rollout of new centers.  On March 3, 1997, the
Company announced that it had engaged an investment banking firm
to arrange a $12 million private placement of equity securities
for the Company. The proceeds of this financing, when completed,
will be used for future rollouts of new laser refractive surgery
centers and for general corporate purposes.  There is no assurance
that the financing will be completed.

Item 7.  Financial Statements.

     The consolidated financial statements for the year ended
December 31, 1996, are included in this Report on Form 10-KSB in
their entirety immediately following the signature pages hereto.

Item 8.  Changes In and Disagreements With Accountants on
Accounting and Financial Disclosure.


     Not applicable.


     PART III

     Item 9.  Directors, Executive Officers, Promoters and Control
Persons; Compliance with Section 16(a) of the Exchange Act.

     Directors and Executive Officers

     The following individuals serve as the Company's directors
and executive officers:

Stephen N. Joffe, age 53,B.S.C., M.B.Ch.B., M.D., F.R.C.S.
(Edin.), F.R.C.S. (Glasg.), F.C.S. (SA), F.A.C.S., is the
President of LCA-Vision.  He was also the founder of LCAV, Inc.
and served as its Chairman of the Board and Chief Executive
Officer since its founding in 1985.  He also founded Surgical
Laser Technologies Inc. in 1983 and served as its Chairman until
January 1990.  In addition, Dr. Joffe is an Esteemed Professor of
Surgery at the University of Cincinnati Medical Center, a position
he has held since 1990.  He was a full-time Professor of Surgery
at the University of Cincinnati Medical Center for nine years
prior to 1990.  Dr. Joffe obtained his medical degree in 1967 from
the University of Witwatersand (South Africa), and was awarded a
post-doctorate degree in 1976.  He has held faculty appointments
at the Universities of London, Glasgow and Cincinnati and holds
fellowships at the College of Surgeons of South Africa, the Royal
College of Surgeons in Edinburgh, the Royal College of Surgeons in
Glasgow, and the American College of Surgeons.  Dr. Joffe led
development efforts in Nd:YAG laser surgical techniques,
established the International Nd:YAG Laser Society, and chaired
the first two meetings.  He is senior editor of six textbooks on
lasers, co-author of Lasers in Medicine, author of over 180 papers
in scientific journals, contributor of chapters to 32 textbooks,
and presenter of over 200 papers before scientific societies in 20
countries throughout the world.

Judith A. Crist, age 53, R.N., M.A., has been Executive Vice
President of Operations since 1987.  She previously held the
position of Director of Operating Room Services at Good Samaritan
Hospital, Cincinnati (1986 1987), Henry Ford Hospital, Detroit
(1984 1986) and Harper-Grace Hospital, Detroit (1982 1984).  Her
prior experience includes positions as operating room staff nurse,
physician's assistant and operating room supervisor.

Larry P. Rapp, C.P.A., age 49, Chief Financial Officer, joined
LCA-Vision in April, 1996.  He has over 20 years of financial
experience in publicly traded and privately held companies and
public accounting  experience with Price Waterhouse.  Prior to
joining LCA-Vision, he was a Principal with Sanctuary Financial
Group, Inc. which provided interim financial management to
entrepreneurial and turnaround companies (1994 1996).  He held
various senior financial management positions with Weinberg
Capital Corporation (1989 1993), Animed, Inc. (1987 1989),
Omnicare, Inc. (1984 1987) and Rotek, Inc. (1983 1984).  Mr. Rapp
received his B.S. in accounting from the University of Dayton.

Gregory A. Livingston, age 37, the Executive Vice President of
Planning and Program Development, is responsible for the design,
development, implementation and management of the excimer laser
surgery centers.  Mr. Livingston previously held the position of
LCAV's Vice President, Marketing & Advertising, where he was
responsible for strategic development, account management,
creative development, public relations coordination, creative
production and staff management.  His New York-based direct
marketing/advertising agency experience covers a broad range of
clients including health care, retail, packaged goods, insurance,
wine and spirits, mail order and publishing.  As of the date of
this report, Mr. Livingston was no longer an executive officer or
full-time employee of the Company.

Sandra F. W. Joffe, age 53, has been Director, Treasurer and
Secretary of the Company since 1986.  Ms. Joffe formerly was a
Director of Surgical Laser Technology Inc. from 1983 1986. 
Previously, she had been a professional educator and involved in
fundraising for non-profit organizations.  Ms. Joffe is the wife
of Stephen N. Joffe.

John C. Hassan, age 54, is President of Champion Printing, Inc. 
Previously, he was Vice President, Marketing of the Drackett
Company, a division of Bristol-Meyers Squibb.  He currently serves
as Treasurer of Printing Industries of Southern Ohio, and is a
board member of the Ohio Graphics Arts Health Fund, the Camargo
Club and serves on the United Way and Fine Arts campaigns.  Mr.
Hassan received his undergraduate degree from Princeton and his
M.B.A. from Dartmouth College.

Craig P. R. Joffe, age 24,  has been a director of the Company
since 1995.  He is a graduate of Columbia University and is
currently studying at Harvard Law School.  Mr. Joffe is the son of
Stephen N. Joffe.

Section 16(a) Beneficial Ownership Reporting Compliance

     Not applicable.

Item 10.  Executive Compensation.

Summary

     The following table summarizes, for the fiscal years
indicated, all annual compensation earned by or granted to the
Company's Chief Executive Officer and the only other executive
officers whose compensation exceeded $100,000 for all services
rendered to the Company in all capacities (the "named executives")
during the last fiscal year:

<TABLE>
                                              SUMMARY COMPENSATION TABLE
<CAPTION>
                    
 
                                                                                       Long-Term 
                                                                                      Compensation 
                                                Annual Compensation                       Awards          

Name and Principal                                                           Securities   All Other
Position                         Year           Salary($)        Bonus($)    Underlying   Compensation       
                                                                             Options(#)   ($)
<S>                              <C>            <C>             <C>          <C>          <C>
Stephen N. Joffe,                1996           $198,000            --           --       $52,534(2)
President and Chief              1995           $547,032(1)         --           --       $60,672(2)
Executive Officer                1994           $605,000(1)         --           --       $51,919(2)


Judith A. Crist,                 1996           $109,400            --                 200,750 shs.                   --
Executive Vice-                  1995           $ 94,600          $25,594                   --                        --
President, Operations

Gregory A. Livingston            1996           $103,800            --                 135,750 shs.                   --
Executive Vice President of
Planning and Program Development 
_________________

</TABLE>

(1)     Dr. Joffe, as a stockholder of Laser Centers of America,
Inc. ("LCA"), an S corporation which merged into the Company on
September 29, 1995, received distributions from the Company. 
These distributions were separate and discrete from the salary and
other compensation paid by the Company to Dr. Joffe and,
accordingly, the amounts set forth herein do not include S
corporation distributions.  See "Certain Relationships and Related
Transactions" herein.

(2)     Includes for 1994, 1995 and 1996, respectively, $4,678,
$5,845 and $5,845, which was a car allowance and $15,104, $14,139
and $778, which were term life insurance and long-term disability
premiums for insurance benefitting named executive.  Also includes
for 1994, 1995, and 1996, respectively, $32,137, $40,688 and
$45,911 placed in a life insurance trust benefitting named
executive.


Stock Options

     The following table sets forth information regarding stock
options granted to the named executives during 1996:

<TABLE>
                        OPTION GRANTS IN LAST FISCAL YEAR                       
<CAPTION>
                                Individual Grants

                          Number of          % of Total    
                          Securities         Options
                          Underlying         Granted to       Exercise of
                          Options            Employees in     Base Price     Expiration
Name                      Granted #(1)       Fiscal Year      ($/Sh.)        Date
________________________  ____________       _____________    ___________    _________
<S>                       <C>                <C>              <C>            <C>                                   
Judith A. Crist                 750          Less than 1%     $5.25           1/1/06

                            200,000          10.2%            $5.25           6/3/06

Gregory A. Livingston           750          Less than 1%     $5.25           1/1/06

                            135,000           6.9%            $5.25           6/3/06


</TABLE>








___________________________________

(1)     The options granted January 1, 1996, first become exerciseable as 
to 25% of the shares covered after the end of each of the first four years 
after the date of grant and are exerciseable in full after the end of four 
years.  Options granted June 3, 1996, first become exercisable as to 20% of 
the shares covered after the end of each of the first five years after
the date of grant and are exercisable in full after the end of
five years.  The option exercise price is not adjustable over the
10-year term of the options except due to stock splits and similar
occurrences affecting all outstanding stock.

     The following table sets forth information regarding stock
options exercised by the named executives during 1996 and the
value of unexercised in-the-money options held by the named
parties as of December 31, 1996:

<PAGE>
<TABLE>
                                    AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR
                                                 AND FY-END OPTION VALUES
<CAPTION>
                                                           Number of Securities            Value of Unexercised In-the-
                                                           Underlying Unexercised          Money Options at FY-End ($) 
                                                           Options at FY-End (#)    


                         Shares 
                         Acquired       Value
                         on Exercise    Realized
Name                     (#)            ($)             Exercisable   Unexercisable         Exercisable    Unexercisable 
________________         ___________    _________       ____________   _____________         ___________    _____________
<S>                      <C>            <C>             <C>           <C>                   <C>
Judith A. Crist              0             0                 0          200,750                  0                0

Gregory A. Livingston        0             0                 0          135,750                  0                0

</TABLE>
 

Director Compensation

     The Company has no standard arrangements for compensation of
directors, except as provided in the LCA-Vision Directors'
Nondiscretionary Stock Option Plan (the "Directors' Plan"), and
all directors served and continue to serve without compensation
directly attributable to their services.  There are no non-standard 
compensation arrangements with directors of the Company. 
The Directors' Plan provides that non-employee directors receive
an initial grant of an option to purchase 75,000 shares of common
stock upon their election to the Board and that thereafter,
following each annual meeting of stockholders they receive an
automatic grant of an option to purchase 1,250 shares of Common
Stock.  All such options have an exercise price equal to the fair
market value on the date of grant.

Item 11.  Security Ownership of Certain Beneficial Owners and
Management.

     Under Section 13(d) of the Securities Exchange Act of 1934
and the rules promulgated thereunder, a beneficial owner of a
security is any person who directly or indirectly has or shares
voting power or investment power over such security.  Such
beneficial owner under this definition need not enjoy the economic
benefit of such securities.  The following table sets forth
information with respect to the beneficial ownership of shares of
Common Stock and Preferred Stock as of March 20, 1997 of each
executive officer, each director, and each stockholder known to be
the beneficial owner of 5% or more of Common Stock, Class A
Preferred Stock, or Class B Preferred Stock and all officers and
directors as a group.
<PAGE>
<TABLE>
<CAPTION>
                                  Name and Address of                         Amount and Nature                   Percent
Title of Class                    Beneficial Owner(1)                         of Ownership                        of Class
<S>                               <C>                                         <C>                                 <C>     
Common Stock                      Stephen N. Joffe, M.D.                      17,731,912 shares owned              90.47%(2)
                                  President and Director                      of record and
                                  8750 Red Fox Lane                           beneficially(2)(3)
                                  Cincinnati, Ohio 45243

Class A                           Stephen N. Joffe, M.D.                      3,376 shares owned of                   51%
Preferred Stock                   President and Director                      record and beneficially
                                  8750 Red Fox Lane
                                  Cincinnati, Ohio 45243

Class B         
Preferred Stock                   Stephen N. Joffe, M.D.                      11 shares of                         87.30%
                                  President and Director                      record and beneficially  
                                  8750 Red Fox Lane
                                  Cincinnati, Ohio 45243
    
Common Stock                      Sandra F.W. Joffe                           3,852,649 shares owned               19.66%
                                  Secretary, Treasurer and Director           of record and 
                                  8750 Red Fox Lane                           beneficially(3)
                                  Cincinnati, Ohio 45243 

Class B                           Sandra F.W. Joffe                           1.6 shares of record                 12.70%
Preferred Stock                   Secretary, Treasurer and Director           and beneficially
                                  8750 Red Fox Lane
                                  Cincinnati, Ohio 45243

Common Stock                      Craig P.R. Joffe                            2,500,313 shares owned               
                                  Director                                    of record and beneficially (2)       12.76%
                                  22 Bigelow Street #2B
                                  Cambridge,  MA 02139

Common Stock                      All directors and executive                 18,248,537 shares owned                     
                                  officers as a group (6 persons)             of record beneficially (4)           90.81%        


Class A                           All directors and executive                 3,376 shares owned of                  51%
Preferred Stock                   officers as a group (6 persons)             record and beneficially

Class B                           All directors and executive                 12.6 shares owned of                  100%
Preferred Stock                   officers as a group (6 persons)             record and beneficially
</TABLE>
(1)     The persons named in the table have sole voting and
investment power with respect to all shares of common stock shown
as beneficially owned by them, subject to community property laws,
where applicable, and the information contained in other footnotes
to this table.

(2)     Includes 5,000 shares which may be voted by Dr. Joffe as
proxy for Sandra F.W. Joffe and Craig P.R. Joffe.  Sandra and
Craig Joffe's share totals set forth above include the shares
under proxy.

(3)     Includes 4,000 shares which are held jointly by Dr. Joffe
and Sandra F.W. Joffe.

(4)     Includes a total of 496,500 shares which may be acquired
upon the exercise of certain unexercised outstanding stock
options.

Item 12.  Certain Relationships and Related Transactions.

     Since January 1, 1995, the Company was a party, directly or
indirectly, to the following transactions with its current
directors, executive officers and principal stockholders
(including any of their associates or affiliates):  

     LCA previously was treated for federal income tax purposes as
an S corporation under Subchapter S of the Internal Revenue Code
of 1986, as amended (the "Code").  In 1995,  prior to the merger
with and into LCA-Vision, LCA declared and paid to its two
stockholders distributions of $8,456,000, in cash, which
constituted payments to the stockholders of LCA's past earnings on
which those stockholders have already paid income taxes under
Subchapter S of the Code.

     Prior to the merger of LCA into the Company, Dr. and Mrs.
Joffe, utilizing a portion of the proceeds of their S corporation
distribution from LCA, agreed to lend a total of $4,390,772 to the
Company, receiving in return, two long term promissory notes for
the principal amount plus interest at a rate of 6.91% per annum. 
All sums due to Dr. and Mrs. Joffe under the promissory notes are
due and payable in full upon the maturity of the promissory notes,
September 26, 2005.  Any or all amounts due under the promissory
notes may be prepaid at any time, without penalty.  During 1995
and 1996, the Company repaid $15,003 and $354,097, respectively.

     Dr. Joffe is the guarantor of approximately $11,080,000 in
bank loans to the Company, including a mortgage note in the amount
of $3,080,000 which remained outstanding at December 31, 1996, and
a working capital credit line of up to $8,000,000 on which
$3,438,000 had been drawn at December 31, 1996.  To date, Dr.
Joffe has not been compensated for these personal guarantees.

     In May 1995, the Company acquired a 45% interest in the
Surgery Center of Georgia, LLC, Atlanta, Georgia ("SCG").  The
transaction was funded entirely by borrowings by SCG.  The Company
guaranteed a portion of SCG's debt.  The Company's principal
stockholder acquired another 35% interest in SCG in a similar
fashion.  In September 1995, the Company's 45% interest in SCG was
distributed to the principal stockholder. The Company remained as
a guarantor on approximately $2,200,000 of SCG's debt on a
temporary basis after the distribution, until the principal
stockholder arranged the elimination of the Company's guarantee
prior to the end of 1995.

     Dr. Joffe is the principal stockholder and majority owner of
The LCA Center for Surgery, Ltd., Cincinnati, Ohio, an Ohio
limited liability company ("The Cincinnati Surgery Center"), which
was organized in September, 1995.  The Company does not hold an
investment in the Cincinnati Surgery Center. The Company has
leased to The Cincinnati Surgery Center, for a period of 20 years
at an annual rental of $190,000, a portion of its office building
located at 7840 Montgomery Road and also will provide to The
Cincinnati Surgery Center accounting, management and
administrative services pursuant to an Administrative Services
Agreement for a fee of $5,000 per month.

     LCA and Dr. Joffe previously owned all of the stock of LCA
Canada, Inc. ("LCA Canada") which owned 67% of the stock of the
Toronto Laservision Centre, Inc. (the "Centre").   LCA and Dr.
Joffe contributed their entire interest in LCA Canada to the
Company in exchange for nominal consideration.  LCA-Vision renamed
the subsidiary LCA-Vision Canada, and on August 31, 1995 acquired
the remaining 33% of the stock of the Centre from certain
unaffiliated holders.  Accordingly, the Centre is now a wholly-owned subsidiary
of the Company, through its subsidiary LCA-Vision
Canada.

     In November and December, 1996, Dr. Joffe entered into debt
conversion transactions with the Company pursuant to which he
converted a total of $2,200,000 of the debt owed to him by the
Company into 11 shares of Interim Series Class B Preferred Stock. 
Similarly, Mrs. Joffe converted a total of $321,672 of debt owed
to her into 1.6 shares of Interim Series Class B Preferred Stock. 
Prior to July 1, 1997, the Interim Series Class B Preferred Stock
is automatically convertible into the same security, if any, which
may be issued to institutional investors in a private placement of
$10,000,000 or more, on the same terms and conditions as the
institutional investors.  From and after July 1, 1997, the Interim
Series Class B Preferred Stock is convertible into Common Stock at
the then current market price of Common Stock, at the option of
the holders.

     PART IV

Item 13.  Exhibits and Reports on Form 8-K.

(a)  Exhibits

Exhibit                                                  
Number       Description of Exhibit     

3(i)         Amended Certificate of Incorporation of
             Registrant, including subsequent updates     Note (a)
                                                          
3(ii)        Amended Bylaws of Registrant                 Note (a)
                                                            
10(a)        LCA-Vision Inc. 1995 Long-Term Stock 
             Incentive Plan                               Note (b)
                                                            
10(b)        LCA-Vision Inc. Directors' Non-Discretionary 
             Stock Option Plan                            Note (b)

10(c)        LCA-Vision Inc. 401(k) Plan                  Note (a)

10(d)        Form of Laser Lease with Prime Leasing, 
             Inc.                                         Note (a)

10(e)        The LCA Surgery Center Real Estate Lease     Note (a)

10(f)        Toronto LaserSight Centre Real Estate Lease  Note (a)

10(g)        Toronto LaserSight Centre Equipment Lease    Note (a)

10(h)        The LCA Surgery Center, Ltd. Administrative 
             Services Agreement                           Note (a)

11           Earnings Per Share Computation

21           Subsidiaries of Registrant

23           Consent of Coopers & Lybrand L.L.P.

24           Powers of Attorney                           Note (c)

27           Financial Data Schedule

             NOTE REFERENCES:

     (a)     Incorporated by reference to the Company's
Registration Statement on Form 10-SB No. 0-27610, which became
effective on January 25, 1996.

     (b)     Incorporated by reference to the Company's Annual
Report on Form 10-KSB for the year ended December 31, 1995.

     (c)     Contained on the first page of the signature pages
contained in this report.

(b)  Reports on Form 8-K

     On December 4, 1996 the Company filed a Current Report on
Form 8-K in which, under Item 5 hereof, the Company reported its
issuance of Interim Series Class B Preferred Stock and certain
Common Stock.  A pro forma balance sheet showing the effects of
such issuances as of September 30, 1996 was included as an exhibit
to such Form 8-K.

<PAGE>
     SIGNATURES

     In accordance with Section 13 or 15(d) of the Securities
Exchange Act of 1934, LCA-Vision Inc., the Registrant, has duly
caused this report on Form 10-KSB dated March 27, 1997 to be
signed on its behalf by the undersigned, thereunto duly
authorized.

                                   LCA-Vision Inc.


Date:     March 27, 1997           By:     /s/ Stephen N. Joffe   
____________________________          ____________________________ 
                                      Stephen N. Joffe, President


                          POWER OF ATTORNEY

     KNOW ALL PERSONS BY THESE PRESENTS, that each person whose
signature appears below hereby constitutes and appoints Larry P.
Rapp, his or her true and lawful attorney-in-fact and agent, with
full power of substitution, and with power to act alone, to sign
and execute on behalf of the undersigned any amendment or
amendments to this report on Form 10-KSB, and to perform any acts
necessary to be done in order to file such amendment or
amendments, with exhibits thereto and other documents in
connection therewith with the Securities and Exchange Commission
and each of the undersigned does hereby ratify and confirm all
that said attorney-in-fact and agent, or his substitutes, shall do
or cause to be done by virtue hereof.

     In accordance with the Securities Exchange Act of 1934, this
report has been signed by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.

Principal Executive 
Officer:                                                Date:



/s/ Stephen N. Joffe          President and        March 27, 1997 
____________________          Chief Executive
                              Officer


Principal Financial and
Accounting Officer:


/s/ Larry P. Rapp            Chief Financial       March  27, 1997 
___________________          Officer 


Directors:


                              Director             March 27, 1997
__________________   
John C. Hassan



/s/ Stephen N. Joffe         Director              March 27, 1997 
____________________
Stephen N. Joffe   

/s/ Sandra F.W. Joffe        Director              March 27, 1997 
____________________
Stephen N. Joffe   

/s/ Craig P.R. Joffe         Director              March 27, 1997 
____________________
Stephen N. Joffe   <PAGE>
     INDEX TO CONSOLIDATED
     FINANCIAL STATEMENTS



                                                       Page Number
Description                                         in this Report

Report of Independent Accountants                              F-1

Consolidated Statements of Operations
    for the years ended December 31, 1996, 1995 and 1994       F-2

Consolidated Balance Sheets
    as of December 31, 1996 and 1995                           F-3

Consolidated Statements of Shareholders' Equity
    for the years ended December 31, 1996, 1995 and 1994       F-4

Consolidated Statements of Cash Flows
    for the years ended December 31, 1996, 1995 and 1994       F-5
      
Notes to Consolidated Financial Statements                     F-7


<PAGE>



     REPORT OF INDEPENDENT ACCOUNTANTS





To the Board of Directors
LCA-Vision Inc.
Cincinnati, Ohio

We have audited the accompanying consolidated balance sheets of
LCA-Vision Inc. and its subsidiaries as of December 31, 1996 and
1995, and the related consolidated statements of operations,
shareholders' equity and cash flows for each of the three years in
the period ended December 31, 1996.  These financial statements
are the responsibility of the Company's management.  Our
responsibility is to express an opinion on these financial
statements based on our audits.

We conducted our audits in accordance with generally accepted
auditing standards.  Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement.  An audit
includes examining, on a test basis, evidence supporting the
amounts and disclosures in the financial statements.  An audit
also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating
the overall financial statement presentation.  We believe that our
audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present
fairly, in all material aspects, the consolidated financial
position of LCA-Vision Inc. and its subsidiaries as of December
31, 1996 and 1995 and the consolidated results of its operations
and its cash flows for each of the three years in the period ended
December 31, 1996 in conformity with generally accepted accounting
principles. 


/s/ Coopers & Lybrand L.L.P.


Cincinnati, Ohio
March 18, 1997

<PAGE>
LCA-VISION INC.

CONSOLIDATED STATEMENT OF OPERATIONS                               
                                                     

<PAGE>
<TABLE>

                                                                              Year Ended December 31,
                                                                              _______________________
<CAPTION>
                                                             1996                   1995                   1994
                                                             ____                   ____                   _____               
<S>                                                      <C>                    <C>                      <C>
Net revenue                                              $13,759,838            $13,651,028              $16,931,835
Direct operating expenses                                  7,732,171              5,980,657                7,290,911
General and administrative 
expenses                                                   7,327,036              6,304,911                6,625,085

Center pre-opening expenses                                  225,349
Depreciation and amortization                              1,597,086              1,042,400                1,246,608
                                                          __________              _________                _________
 
Income (loss) from operations                            ( 3,121,804)               323,060                1,769,231
Equity in income (loss) from
   unconsolidated affiliates                             (   905,993)                40,377                  107,535

Interest income                                               89,130                158,406                   54,125

Interest expense                                         (   769,816)            (  309,464)             (   131,867)

Other income (expense)                                       105,674                 10,390              (   102,493)

Gain on sale of investment in  
   unconsolidated affiliate                                  545,903               __________               __________

Income (loss) before income tax                          ( 4,056,906)               222,769                1,696,531

Income tax expense                                        ___________           (    44,005)                __________

Net income (loss)                                       $( 4,056,906)         $     178,764             $  1,696,531
                                                        _____________         ______________            ______________
                                                        _____________         ______________            ______________

(Loss) per share                                        $      (0.21)
                                                        _____________
                                                        _____________

Weighted average number of
 common shares outstanding                                19,609,505


Pro forma income data (unaudited)
   Net income as reported                                                     $     178,764             $  1,696,531
   Provision for income taxes - pro forma                                       (    40,600)             (   645,000)
                                                        _____________           ____________             ____________
    
   Pro forma net income                                                       $     138,164             $  1,051,531
                                                        _____________           _____________            ____________
                                                        _____________           _____________            ____________
   
   Pro forma earnings per share                                               $         .02             $       1.05
                                                        _____________          _______________          ______________
                                                        _____________          _______________          ______________

   Pro forma weighted average number of 
      common shares outstanding                                                   5,659,208                1,000,000



The accompanying notes are an integral
part of this statement
LCA-VISION INC.

</TABLE><TABLE>

CONSOLIDATED BALANCE SHEETS
<CAPTION>
                                                  December 31,
                                                1996          1995
<S>                                     <C>                 <C>
ASSETS  
   Current assets:
     Cash and cash equivalents          $     724,026       $  2,587,152
      Accounts receivable, net                949,728          1,866,249
      Inventory                               245,000            675,195
      Prepaid expenses and other              984,674            581,120
                                              _______          _________

      Total current assets                  2,903,428          5,709,716
   Property and equipment, net              9,455,518          6,207,065
   Investment in affiliates                   218,578            443,588
   Long-term receivables                      440,745             16,343
   Other assets                               692,175          1,149,197
   Total assets                           $13,710,444        $13,525,909
                                           ==========         ==========



LIABILITIES and SHAREHOLDERS' EQUITY
   Current liabilities
      Note payable to bank               $  3,438,000
      Accounts payable                        782,973       $   734,265
      Accrued liabilities and other         1,045,770         1,344,867
      Current  portion of: 
        Long-term debt                        184,632           129,214
        Capital lease obligations             638,895           221,436
                                            _________         __________

     Total current liabilities              6,090,270         2,429,782
   Long-term debt                           4,465,155         7,537,954
   Capitalized lease obligations            1,957,382           939,190
                                            _________         _________

   Total liabilities                       12,512,807        10,906,926
   Commitments and Contingencies
   Shareholders' Equity
      Preferred stock                       2,521,679                 7
      Common stock                             78,835            78,156
      Additional paid-in capital            3,177,278         3,068,818
      Retained (deficit)                  ( 4,592,214)    (     535,308)
      Translation adjustment                   12,059             7,310
                                           __________      _____________

   Total shareholders' equity               1,197,637         2,618,983
                                           __________      _____________

   Total liabilities and shareholders' 
   equity                                 $13,710,444       $13,525,909
                                          ============     =============



                                                      The accompanying notes are an integral
                                                                     part of this statement

/TABLE
<PAGE>
<TABLE>

LCA-VISION INC.

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY

<CAPTION>
                                                                                     Year Ended December 31,
                                                                  1996                     1995                     1994
<S>                                                          <C>                    <C>                     <C>
Class A Preferred Stock:
        Beginning balance: 1,688; 1,688; and 0 outstanding   $         7            $           7                     
        Shares issued to effect merger: 1,688 shares           ___________           _______________        ______________          
                                                                                                            $          7          
        Ending balance:  1,688; 1,688; 1,688 outstanding     $         7            $           7           $          7
                                                              ================       ===============         ==============
Class B Preferred Stock:
        Shares issued under shareholder debt conversion:
         12.6 shares                                         $ 2,521,672
                                                              ____________
   Ending balance:  12.6 outstanding                         $ 2,521,672
                                                              ============

Common Stock:  .001 par value, 
      110,000,000 shares authorized
        Beginning balance: 19,538,977; 1,000,000; 
      1,000,000 outstanding                                 $     78,156            $       4,000           $      4,000
        Shares issued to effect merger: 18,246,477 shares
        Sale of shares:  44,444 and 292,500 shares                    44                   72,986
        Other:  6,591 shares                                         635                    1,170   
                                                            ______________
     
   Ending balance:  19,590,012; 19,538,977; 
      1,000,000 outstanding                                 $     78,835            $      78,156           $      4,000
                                                            ____________            _____________           _____________
                                                            ____________            _____________           _____________
Additional Paid-in Capital     
   Beginning balance                                        $  3,068,818            $    491,597           $    471,702 
Other                                                              8,504                  19,895
        Shares issued to effect merger                                                 2,229,155
        Sale of shares                                            99,956                  587,831
        Distribution to shareholders                                                   (  239,765)          ______________
   Ending balance                                           $  3,177,278               $3,068,818             $  491,597
                                                            ____________            _____________           _____________
                                                            ____________            _____________           _____________
Retained Earnings (Deficit)
   Beginning balance                                        $(   535,308)              $7,502,334             $6,907,573
   Net income (loss)                                         ( 4,056,906)                 178,764              1,696,531
   Distribution to shareholders                                                        (8,216,406)            (1,101,770)
                                                              ____________             ___________            ___________   
  Ending balance                                            $( 4,592,214)             $  (535,308)            $7,502,334
                                                             ==============            ============           ===========
Foreign Currency Translation Adjustment
        Beginning balance                                   $      7,310
        Changes during the year                                    4,749              $     7,310
                                                            ______________            _____________

   Ending balance                                           $     12,059              $     7,310
                                                            ==============            ==============



                                         The accompanying notes are an integral
                                                  part of this statement

</TABLE>

<TABLE>

LCA-VISION INC.

CONSOLIDATED STATEMENT OF CASH FLOWS

<CAPTION>
                                                            Year Ended December

                                                           1996               1995          1994


<S>                                                         <C>              <C>            <C>
Cash flows from operating activities:
Net income (loss)                                           $(4,056,906)     $   178,764    $ 1,696,531
Adjustments to reconcile net income (loss)
   to net cash provided (used) in operating activities:
   Depreciation and amortization                              1,597,086        1,042,400      1,246,608
   Equity in loss of unconsolidated affiliates                  905,993
   (Gain) loss on sale of investments                        (  575,903)          63,102         33,688
   (Gain) on disposal of equipment                           (   53,546)      (  120,625)    (   60,565)
   Provision for doubtful accounts receivable                   144,591          153,312     (   12,312)
   Write off of intangibles                                     106,772           63,230
   Changes  in operating assets and liabilities
      (Increase) decrease
         Accounts receivable                                  1,044,285          147,688      1,356,589
         Inventory                                               92,249          280,349         34,377
         Prepaid and other                                  (   155,604)      (  158,899)    (   62,049)
         Other assets                                            50,133       (  146,604)    (  187,934)
      Increase (decrease)
         Accounts payable                                        48,708          346,623     (  360,799)
         Accrued liabilities and other                      (    41,646)         393,346        218,537
                                                             ___________      ___________     __________

Net cash provided (used) by operations                      (   893,788)       2,242,686      3,902,671

Cash flows from investing activities:
   Property and equipment additions                          (2,747,485)      (1,818,126)     ( 771,722)
   Investment in unconsolidated affiliates                   (1,099,126)
   Loans and advances to unconsolidated affiliates           (  713,100)
   Acquisition of business                                   (  149,439)          66,858
   Purchase of intangibles                                   (   40,536)      (  167,768)    (   26,612)
   Proceeds from sales of equipment                             132,676          338,849        236,403
   Proceeds from sale of investment                           1,000,000
                                                             ____________     _____________    ___________  

Net cash used by investing activities                        (3,617,010)      (1,580,187)     ( 561,931)

                               The accompanying notes are an integral
                                         part of this statement

</TABLE>
<TABLE>

LCA-VISION INC.

CONSOLIDATED STATEMENT OF CASH FLOWS  (continued)                                                                    

<CAPTION>
                                                            Year Ended December

                                                           1996                 1995          1994


<S>                                                        <C>                <C>           <C>
Cash flows from financing activities:
   Net borrowing under line of credit                       $  3,438,000                   $(   345,105)
   Proceeds from long-term notes payable                                       7,590,772
   Repayment of long-term notes payable and
      capitalized lease obligations                          (  545,369)      (1,943,749)   (    56,811)
   Repayment of notes payable to shareholders                (  354,097)      (   15,003)
   Proceeds from sale of common stock                           100,000        2,891,149
   Distribution to shareholders                                               (8,456,171)   ( 1,101,770)
   Other                                                          9,138       (    3,656)    ___________
                                                             ___________      ___________    ___________                   
     
Net cash provided (used) by financing activities              2,647,672           63,342    ( 1,503,686)
                                                             ___________      ___________    ___________

Net increase (decrease) in cash                              (1,863,126)         725,841      1,837,054

Cash at beginning of year                                     2,587,152        1,861,311         24,257
                                                              __________      __________     ___________

Cash at end of year                                         $   724,026     $  2,587,152   $  1,861,311
                                                             ===========     ===========    ============

Supplemental disclosures:
   Interest paid                                            $   488,729
                                                             ==========
   Notes payable shareholders converted
      to preferred stock                                    $ 2,521,672
                                                             ==========

   Inventory sold for long-term notes receivable            $   247,946
                                                             ==========

   Capital lease obligations entered into                   $ 2,264,655     $(   971,700)
                                                             ==========      ============ 
   Transfer of equipment under capital lease
      to affiliate                                          $   485,850
                                                             ==========







     The accompanying notes are an integral
     part of this statement

</TABLE>


1.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 

Organization

On September 29, 1995, LCA-Vision Inc. ("LCA-Vision" or the
"Company") merged with Laser Centers of America, Inc. ("LCA").  At
the time of the merger, two shareholders together owned 92% of the
outstanding voting stock of LCA-Vision and 100% of LCA's.  The
financial statements reflect the historical assets and liabilities
and results of operation of LCA prior to the merger.  Shareholders'
equity was restated to reflect the capital structure of LCA-Vision
at the time of the merger.

Immediately prior to the merger, LCA distributed $6,390,772 to its
shareholders which represented a portion of the subchapter S
corporation earnings previously included in the taxable income of
its shareholders.  The proceeds of the distribution were used by the
shareholders to acquire shares of LCA-Vision common stock for $2
million and to loan the remainder to LCA-Vision, receiving two
promissory notes.

Business

LCA-Vision is a leading developer and operator of free-standing
laser refractive surgery centers.  The Company also manages laser
and minimally invasive surgery programs for hospitals and medical
centers. 

The laser refractive surgery centers operated by the Company provide
the facilities, equipment and support services for performing
various corrective eye surgeries that employ state-of-the-art laser
technologies.  The surgeries performed in the Company's centers
primarily include photorefractive keratectomy ("PRK") for treatment
of myopia (nearsightedness).  As of December 31, 1996, the Company
had twelve laser refractive surgery facilities in the United States,
two in Ontario, Canada, and one in Helsinki, Finland.  The Company
opened two centers in January 1997 -- Albany, New York and Mountain
View, California.

The Company manages 26 multi-specialty laser surgery programs at
various medical facilities on a contract basis.  The Company
structures its contractual arrangements to match compensation with
the value of the specific services it provides.  The Company is
generally paid on a fixed amount for the initial work performed to
render a center operational and then receives compensation to
service a center on an ongoing basis.  Compensation is generally
fixed based on procedures performed; based on increased surgical
volume or reduced surgical costs; or a combination of such. 
Contracts may also compensate the Company for conducting the
education and marketing programs of the surgical center and its
staff including doctors.

Principles of Presentation

The consolidated financial statements include the accounts of LCA-Vision Inc., 
a Delaware corporation, and its wholly-owned
subsidiaries after elimination of intercompany balances and
transactions.  Certain reclassifications of prior year numbers have
been made to conform with the current presentation.

Stock Split

In June 1996, the shareholders approved a one-for-four reverse stock
split of the Company's common and preferred stock.  The number of
shares and per share data in these consolidated financial statements
have been adjusted retroactively to give effect to these splits as
if they had occurred at the beginning of the earliest period
presented.

Use of Estimates

The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at
the dates of the financial statements and the reported amounts of
revenues and expenses during the reporting periods.  Actual results
could differ from those estimates.

Cash and Cash Equivalents

Cash includes cash on hand or in banks available for immediate
dispersal.  Cash equivalents are short-term investments that have an
original maturity date of less than 90 days.

Inventory

Inventory is valued at the lower of cost (first-in, first-out) or
market. 

Property and Equipment

Property and equipment are stated at cost.  The Company provides for
depreciation and amortization using the straight-line method which
recognizes the cost over the estimated useful lives of the
respective assets, or as to leasehold improvements, the term of the
related lease if less than the estimated useful life.

Per Share Data

Earnings per share is computed by dividing net income (loss) by the
weighted average number of shares of common stock outstanding. 
Common equivalent shares from Class B preferred stock (using the as-if 
converted method) and from stock options (using the treasury
stock method) have been excluded from the 1996 computation because
their inclusion would be antidilutive.

Pro forma net income per share for the years ended December 31, 1995
and 1994 is based on 22,636,832 and 1,000,000 shares, respectively,
of common stock outstanding, reflecting the recapitalization for the
merger.  The weighted average shares at December 31, 1995 includes
shares issued in conjunction with the merger, as outstanding for
three months.

Fair Value of Financial Instruments

The carrying value of the Company's financial instruments, including
cash and cash equivalents, trade receivables and payables,
approximates their fair value due to their short term maturities. 
The fair values of the Company's long-term debt  is estimated based
on comparison with similar issues or current  rates offered to the
Company for debt of the same remaining maturities.  The estimated
fair values of the Company's long-term debt approximates its fair
value.

Investments in Unconsolidated Affiliates

The equity method is used for investments in laser refractive
surgery centers in which the Company has 50% or less ownership. 
These investments are recorded at the Company's initial investment,
increased or decreased by the Company's share of the center's 
income or loss, less distributions received.

Pre-opening Costs

Costs associated with the opening of a new laser refractive surgery
center are expensed during the first month of the center's
operation.

Concentration of Credit Risk

Financial instruments which potentially subject the Company to
concentrations of credit risk consist principally of trade
receivables.  Credit risk associated with this concentration is
limited due to the number and geographic disperson of the accounts
and the overall stability of the hospital industry.  Management
believes that adequate provision has been made for this credit risk.

Impact of Recently Issued Accounting Standards

In March 1995, the FASB issued Statement No. 121, Accounting for the
Impairment of Long-Lived Assets and for Long-Lived Assets to Be
Disposed Of, which requires impairment losses to be recorded on
long-lived assets used in operations when indicators of impairment
are present and the undiscounted cash flows estimated to be
generated by those assets are less than the assets' carrying amount. 
Statement 121 also addressed the accounting for long-lived assets
that are expected to be disposed of.  The Company adopted Statement
121 in the first quarter of 1996 and the effect is not material to
the Company's operations or financial position taken as a whole. 
Under SFAS No. 121, property and equipment of the Company are
reviewed for impairment whenever events or circumstances indicate
that the asset's undiscounted expected<PAGE>
cash flows are not sufficient to 
recover its carrying amount.  The Company measures an impairment loss 
by comparing the fair value of the asset to its carrying amount.  Fair value
of an asset is calculated as the present value of expected future cash flows.

In October 1995, the FASB issued Statement No. 123, Accounting for
Stock-Based Compensation, which provides an alternative to APB
Opinion No. 25, Accounting for Stock Issued to Employees, in
accounting for stock-based compensation issued to employees.  The
Statement allows for a fair value-based method of accounting for
employee stock options and similar equity instruments.  However, for
companies that continue to account for stock-based compensation
arrangements under Opinion No. 25, Statement No. 123 requires
disclosure of the pro forma effect on net income and earnings per
share of its fair value-based accounting for those arrangements. 
The Company adopted Statement No. 123 in the first quarter of 1996
and has elected to continue to account for stock-based compensation
arrangements under APB Opinion No. 25.


<PAGE>
<TABLE>

2.    COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS

<CAPTION>
                                                                December 31,

                                                         1996                     1995
<S>                                                    <C>                   <C>
Receivables:
   Trade receivables                                   $  1,049,964          $   2,094,249
   Allowance for doubtful accounts                        ( 100,236)               228,000)
                                                        ____________          _____________

                                                       $    949,728          $   1,866,249
                                                        ============          ============= 

Inventory:
   Surgical lasers                                     $    210,000          $     325,000
   Surgical supplies                                         35,000                  4,815
   Product inventory                                                               345,380
                                                        ___________           _____________
  
                                                       $    245,000          $     675,195
                                                        ============         ===============

In December 1996, the Company sold its products 
inventory at book value ($247,946) and received a 
two year note.  The note bears interest
at 9.25% and requires monthly payments of interest 
and principal.

Prepaid Expenses and Other:
   Prepaid insurance                                    $   205,749          $      33,873
   Miscellaneous receivables                                300,020                272,727
   Other                                                    478,905                274,520
                                                        ___________           ____________

                                                       $    984,674          $     581,120
                                                        ===========           ============



                                                                December 31,
                                                         1996                1995


Property and Equipment:
   Land                                           $    375,000   $     375,000
   Building and improvements                         4,929,192       4,034,233
   Leasehold improvements                              211,962          93,453
   Furniture and fixtures                              570,674         355,096
   Equipment                                         2,966,836       2,078,907
   Equipment held under capital leases               2,818,778       1,041,884
   Vehicles                                            140,587         140,587
                                                   ___________     _________
                                                    12,013,029      8,119,160
   Accumulated depreciation and amortization       ( 3,060,276)   ( 1,956,998)
                                                   ____________   ___________ 

                                                     8,952,753      6,162,162

   Construction in progress                            502,765         44,903
                                                   ____________    ___________

                                                   $ 9,455,518    $ 6,207,065
                                                   ============    ==========

Depreciation expense was $1,503,268; $884,886; and $965,342 in 1996, 1995 and 
1994, respectively.  Depreciation and amortization is provided based on the 
following useful lives:  building and improvements -- 5 to 31 years; furniture 
and fixtures -- 5 to 7 years;
equipment -- 

5 years; and vehicles -- 5 years.

Other Assets
   Deposits - lasers                             $   262,500       $   440,425
   Equipment held for lease or resale, net            48,267           328,480
   Advertising production materials, net             44,865           208,273
   Goodwill, net                                    133,863            10,000
   Other                                            202,680           162,019
                                                  __________        __________

                                                  $  692,175       $ 1,149,197
                                                  ==========        ========== 
Accrued Liabilities and Other
   Accrued interest - shareholder notes          $  357,864       $    77,458
Accrued wages                                        20,000           255,000
   Deferred revenue                                 229,942           506,745
   Other                                            461,932           505,664
                                                 __________        __________

                                                $ 1,069,738       $ 1,344,867

</TABLE>                                         ==========        ==========
3.   ACQUISITIONS

On October 28, 1996, the Company purchased the outstanding shares
of 938051 Ontario Inc. ("The Eye Laser Centre").  The terms of the
acquisition provided, among other things, for the Company to pay
$160,000 in cash and provide a letter of credit in the amount of
$64,000 to be held in escrow pending the earlier of the following: 
(1) dismissal of a patent infringement lawsuit filed against one of
the sellers, or (2) settlement or final court determination of the
lawsuit.  In addition, the Company may be required to issue
unregistered common stock with a total market value of $280,000 or
cash totaling $224,000 based on whether The Eye Laser Centre
achieves certain performance objectives.  The acquisition of The Eye
Laser Centre has been accounted for using the purchase method of
accounting.  The purchase price in excess of the net assets acquired
($124,175) has been recorded as goodwill which will be amortized
over 5 years.

On August 31, 1995, the Company acquired the minority interest (33%)
of Toronto Laservision Centre (1992), Inc. ("Centre") for
approximately $140,000.  The Company previously owned 67% of the
Centre; however, it did not have control of the activities or the
business affairs of the Centre because of the terms of a
shareholders' agreement.  Accordingly, the Company recorded its
investment in the Centre using the equity method until August 31,
1995, at which time the acquisition was accounted for as a purchase
and consolidated in the financial statements of the Company.  The
Company recorded approximately $100,400 and $51,600 of equity in
income of the Centre for the eight months ended August 31, 1995 and
the year ended December 31, 1994, respectively.


4.   FINANCING ARRANGEMENTS

Note Payable to Bank

The Company has an $8,000,000 line of credit with a bank which
matures on July 1, 1997.  Interest on borrowings under the line of
credit is at the bank's prime rate (8.25% at December 31, 1996) plus
1%.  Prior to February 1, 1997, interest on borrowings under the
line of credit was at the bank's prime rate less 1%.  The weighted
average interest rate of borrowings under the line of credit during
1996 was 7.38%; there were no borrowings under the line of credit
during 1995.  The assets of the Company serve as collateral for the
line of credit.

Long-Term Debt

Long term debt consists 
of the following:                           December 31,
                                      1996            1995
Mortgage and notes payable         $  3,149,787          $ 3,291,399
Notes payable - shareholders          1,500,000            4,375,769
                                      __________          __________

                                      4,649,787            7,667,168

Current portion                       ( 184,632)           ( 129,214)
                                       __________         __________

                                    $ 4,465,155          $ 7,537,954
                                     ==========         ===========



Mortgage and Notes Payable

During 1995, the Company refinanced the mortgage related to its
building.  The bank loaned a total of $3,200,000, the proceeds of
which were used to repay the existing mortgage ($1,895,000) and
finance improvements to the property.  On April 1, 1996, the
agreement converted to a seven year term loan with monthly principal
payments of $13,333 and a payment of $2,093,334 due April 1, 2003. 
During the remaining term of the loan, the Company can fix the rate
of interest for one, three or five years based on United States
Treasury Notes with the same maturity plus 1.9%.  The interest rate
in effect until April 1, 1997, is 7.7%.

The Company also has a note payable collateralized by certain laser
equipment.  The note requires monthly payments of principal and
interest of $3,420 (Canadian) and bears interest at the Royal Bank
of Canada prime rate plus 1.75%.

Maturities of long-term debt for the five years subsequent to
December 31, 1996 are:  1997 -- $184,632; 1998 -- $187,010; 1999 --
$178,809; 2000 -- $160,000; and 2001 -- $160,000.

The Company's principal shareholder has guaranteed borrowings under
the line of credit and the mortgage note payable.  These agreements
also require the principal shareholder to maintain ownership of at
least 50% of the common stock of the Company unless such change in
ownership results from a public offering of the Company's common
stock.  The Company's loan agreements with its primary lender
contain a provision whereby the Company would be in default if, in
the Bank's reasonable opinion, an event occurs which has a material
adverse effect on the Company's financial condition of operations.

An entity owned by the Company's principal shareholder has loan
agreements with the Company's primary lender.  The loan agreements
do not contain restrictive financial covenants but do provide that
an event of default occurring under the agreements with the entity
owned by the Company's principal shareholder is also a default under
the Company's loan agreement.  Both entities were in compliance with
the provisions of the loan agreements at December 31, 1996.

Notes Payable - Shareholders

The notes payable - shareholders mature on September 25, 2005, and
bear interest at 6.91%.  The promissory notes can be repaid, in
whole or in part, prior to maturity without penalty.  In 1996, the
Company repaid $354,097 of the notes.  In two separate transactions
in December 1996, the shareholders converted $2,521,672 of their
notes into Class B preferred stock (see note 5).  At December 31,
1996, the Company owes the shareholders principal and interest
totaling $1,857,864.


5.   INVESTMENTS IN UNCONSOLIDATED AFFILIATES

The Company is an investor in four entities that own and operate
laser eyecare surgery centers:

                                                 Ownership
                                                 Percentage
                                                 __________

     The Baltimore Laser Sight Center, Ltd.         45%
     Excimer Associates LLC                         40
     The Georgia Laser Sight Center, Ltd.           33.3
     Silmalaseri Oy                                 43

The Company has contracts to provide a variety of fee-based services
to the above companies except for Silmalaseri Oy.

Summary financial information for these investments reported on the
equity method of accounting is as follows:

                                                   1996

     Financial Position:
        Current assets                        $ 1,112,553
        Total assets                            2,188,924
        Total liabilities                       2,479,131
        Members' (deficit)                     (  290,207)

     Operating Results:
        Revenue                              $  1,613,978     
        Net (loss)                             (2,610,097)

The Company's share of the losses of one of its investees exceeds
the carrying amount of the Company's investment and advances.  The
Company has not provided for the additional losses.  The Company
will not record its share of income for this investee until its
share of that net income equals the share of net losses not
recognized.

Revenue for management services performed for the investees was
$417,529 in 1996.  The Company was reimbursed approximately
$1,613,000 for marketing services performed on behalf of the
investees.  The Company wrote down the long term receivable due from
one of its investees.  A charge to income of $272,355 was recorded
in 1996.

The Company sold its investment in Continuum Biomedical, Inc. which
had been accounted for using the equity method for $1,000,000,
resulting in a gain of $545,903.  The gain was recorded in the first
quarter of 1996.

          

6.   PREFERRED STOCK

In June 1996, the stockholders of the Company approved a decrease
to the number of authorized shares of Class A Preferred Stock from
10,000,000 shares to 1,688 shares.  In addition, the stockholders
approved an additional class of preferred stock ("Class B Preferred
Stock").  The Company is authorized to issue up to 5,000,000 shares
of Class B Preferred Stock and the Board of Directors has discretion
to determine its terms without further stockholder approval.  The
holders of the Class B Preferred Stock cannot be granted voting
rights superior to the voting rights of any other existing class of
stock authorized for issuance by the Company.

Preferred stock is comprised of:

                                               December 31,
                                         1996               1995

Class A, $.001 par value, 
1,688 shares authorized,
   1,688 shares issued ($67,510 
   aggregate liquidation preference)     $     7          $     7


Class B, $.001 par value, 
5,000,000 shares authorized,
   7% dividend
   First Interim Series, 
   6 shares issued ($1,200,000 
   aggregate liquidation preference)       1,200,000  

   Second Interim Series, 6.6 shares 
   issued ($1,321,672 aggregate 
   liquidation preference)                  1,321,672     __________
                 

                                        $2,521,679        $      7
                                         =========       ===========

The holders of the Class B interim series preferred stock have the
right to convert the preferred stock into common stock beginning
July 1, 1997.  The conversion price is the average of the closing
bid prices of the Company's common stock for the 30-trading-day
period ending three (3) days prior to the date of conversion.  The
shares are automatically converted into any class or series of
equity securities of the Company issued pursuant to a private
placement of equity securities effected on or before June 30, 1997
and with gross proceeds of at least $10,000,000.  In the event of
a private placement that does not meet the above criteria, the
holders of the securities have the right to convert on a pro rata
basis.  The conversion price is the price per share of the shares
issued in connection with the private placement.      


7.   INCOME TAXES

There is no provision or benefit for current income taxes in 1996
as a result of the operating losses.  Income tax expense, current
for 1995 is comprised of:  Federal - $10,500 and Foreign - $33,505.


Significant components of the Company's deferred tax assets and
liabilities are:

                                          December 31,
                                   1996                    1995

Net operating loss carryforward   $ 1,000,000          $    90,800
Accounts receivable                     17,000                24,500
Inventories                             70,400                47,300
Marketable securities                 138,400              138,400
Property and equipment                 194,800                57,600
Notes payable to shareholders          143,200                31,000
Other                                   45,800               25,000
Equity investments                     330,400           ( 109,800)
                                    ----------          ----------

Net deferred tax assets           $ 1,940,000          $   304,800
                                   ===========          ========== 

Valuation allowance                $(1,940,000)          $ (304,800)
                                   ===========          ==========


The Company has recorded a valuation allowance against deferred tax
assets because there is no assurance that the Company can generate
taxable income sufficient to realize such.

At December 31, 1996, the Company had net operating loss
carryforwards for income tax purposes of approximately $2,500,000
which expire in 2010 and 2011.

Prior to the merger described in Note 1, the Company elected to be
taxed as a subchapter S corporation.  Income tax liabilities, other
than certain state and local income taxes, were included in the tax
returns of the shareholders.  The state and local income taxes
recorded by the Company as general and administrative expense prior
to the merger approximated $36,000 and $48,000 for 1995 and 1994,
respectively.


8.   LEASES

The Company leases certain office space for its laser refractive
surgery centers under operating leases and its lasers under capital
lease arrangements.


Future minimum payments are:

                                                Noncancellable
                         Capital                Operating
                         Leases                 Leases       
                         -------                ----------------

     1997                $   754,514            $   675,730
     1998                    689,471                647,500
     1999                    689,471                544,370
     2000                    668,570                538,370
     2001                    125,137                383,330
     Thereafter                5,202
                             -------
                           2,932,365
 Less amounts 
 representing interest    (  336,088)
                           ----------
Capital lease obligations  2,596,277
 Less current portion     (  638,895)
                           ----------
                         $ 1,957,382
                          ===========



9.   BENEFIT PLANS

In December, 1995, the Company adopted the LCA-Vision Inc. 1995 Long
Term Stock Incentive Plan which permits the issuance of options,
stock appreciation rights ("SARs") or stock to employees and
independent contractors of the Company.  This plan replaced the 1986
Incentive Stock Options Plan which was terminated and all
outstanding options were cancelled in connection with the merger
described in Note 1.  The plan reserves a maximum of 2,500,000
shares of common stock to be subject to the plan and provides that
awards under the plan shall be determined by the committee of the
Board of Directors ("Committee") designated to administer the plan.

Under the terms of the plan, options granted may be either non-qualified or 
incentive stock options and the exercise price may not
be less than the fair market value of a share on the date of grant. 
The Committee determines when options shall be exercisable; however,
the options granted in 1996 generally become exercisable in
installments of 20% per year on each of the first through fifth
anniversaries of the grant date.  The maximum term of any incentive
option is ten years.  SARs may be granted in such form as the
Committee may determine.  Stock awards may be granted only in
payment of incentive compensation.


Information regarding the 1995 Long Term Stock Incentive Plan
follows:
<PAGE>
                                             Exercise Price        
                                           ___________________

                                 Number of             Weighted
                                 Shares      Actual    Average
                                __________  ________   _________
  
Options outstanding at 
  December 31, 1995                 -0-
   Granted                      1,969,250  $2.25 - $5.25  4.92 

  Cancelled                      (178,125)         $5.25
Options outstanding at 
  December 31, 1996             1,791,125  $2.25 - $5.25
                                ==========

Exercisable at 
  December 31, 1996               334,113  $2.56 - $5.25  4.77
                                ==========

Reserved for future option grants 
   at December 31, 1996           708,875
                                ==========

<PAGE>
The Company also adopted the LCA-Vision Inc. Director's
Nondiscretionary Stock Option Plan which provides for the grant of
stock options to the Company's non-employee directors at the fair
market value of the Company's common stock at the date of grant. 
Under this plan, non-employee directors are automatically granted an
option to purchase 75,000 shares of the Company's common stock upon
election or appointment to the Board and an option to purchase 1,250
of the Company's common stock at the time of every annual
organizational meeting of directors following the 1996 annual
meeting of shareholders.  Such options become exercisable at the
rate of 20% per year at the end of each of the first five years
following issuance and the options terminate at the expiration of
the five-year period.  A total of 1,250,000 shares are reserved for
issuance under this plan.  

Options for 150,000 shares with an exercise price of $8.00 per share
were granted in accordance with the LCA-Vision Inc. Director's
Nondiscretionary Stock Option Plan during 1996.  No options were
exercised or cancelled and 1,100,000 shares are reserved for future
option grants.

The Company has adopted the disclosure-only provisions of SFAS No.
123, "Accounting for Stock-Based Compensation", but applies
Accounting Principles Board Opinion No. 25 and related
interpretations in accounting for its employee option plans. The
weighted fair value of the options granted in 1996 was $4.15 per
share.  Compensation expense was immaterial for 1996.  If the
Company had elected to recognize compensation cost based on the fair
value at the grant dates for awards under those plans, consistent
with the method prescribed by SFAS No. 123, net loss and loss per
share would have changed to the following pro forma amounts: 

                                    Net               (Loss) per
                                   (Loss)               Share   
                                   ------             ----------

     As reported                $(4,056,906)            $(0.21)
     Pro forma                  $(4,862,631)            $(0.25)

The fair value of Company stock options used to compute pro forma
net (loss) and (loss) per share disclosures was determined using the
Block-Scholes option-pricing model with the following weighted
average assumptions:  dividend yield of 0%; expected volatility of
98%; risk free interest rates on the date of grant ranging from
5.34% to 6.82%; and an expected holding period of 5 years, the
vesting period of the options granted.

The Company has a savings plan ("Plan") under Internal Revenue Code
Section 401(k).  All full time employees are covered by the Plan. 
The Plan contains two elements -- employee salary contributions and
discretionary employer contributions.  No discretionary employer
contributions were made in 1996, 1995 or 1994.

10.   RELATED PARTY TRANSACTIONS

The Company's principal shareholder is the majority owner of the LCA
Center for Surgery, Ltd. ("Surgery, Ltd.").  Surgery, Ltd. occupies
a portion of the Company's office building for which the Company
recorded income of $182,764 in 1996.  The Company also provided
certain administrative and marketing services for which it recorded
income of $161,563.  Included in accounts receivable at December 31,
1996 is $15,912 due from Surgery, Ltd.

In May 1995, LCA and its principal shareholder acquired 45% and 35%
ownership interests, respectively, in the Surgery Center of Georgia,
LLC ("SCG") in return for guarantees of certain debt of SCG.  As
part of the merger and restructuring  (see Note 1), LCA distributed
its interest in SCG in return for removal from the guarantees of
SCG's debt.  The 1995 financial statements do not include any of the
operating results of SCG during the period LCA had an ownership
interest as it was not LCA-Vision's intent for SCG to be part of the
ongoing business of LCA-Vision following the merger.  In 1996 LCA-Vision 
recorded income of $59,044 for administrative and marketing
services provided to SCG.  Included in accounts receivable at
December 31, 1996, is $90,495 due from SCG.

The Company provided a $60,000 advance to an officer in 1995.  The
advance is supported by a promissory note due November 29, 1996,
with interest payable at 8.75%.  The note was extended and at
December 31, 1996, principal and interest of $65,811 is included in
prepaid expenses and other.  In January 1997, the officer repaid
$30,000 of the balance due by selling to the Company 10,909 shares
of its common stock at the then market value.

11.   COMMITMENTS AND CONTINGENCIES

The Company is insured with respect to medical malpractice risks on
a claims-made basis.  The lawsuit filed against the Toronto
Laservision Centre was dismissed without cost in 1996.

The Company has ordered, and taken delivery of, VISX excimer lasers
for five of its recently opened laser refractive surgery centers. 
The total cost of these lasers is $2,625,000.  The Company
anticipates obtaining lease financing for these lasers.  The Company
has a commitment letter from a leasing agent for three of the lasers
and has obtained proposals for the remainder.